Cocrystal Pharma – Consensus Indicates Potential 225.3% Upside

Broker Ratings

Cocrystal Pharma found using ticker (COCP) have now 2 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 5 and 4.5 with the average target price sitting at 4.75. Given that the stocks previous close was at 1.46 this would imply there is a potential upside of 225.3%. The 50 day MA is 1.54 and the 200 moving average now moves to 1.35. The company has a market cap of $106m. You can visit the company’s website by visiting: http://www.cocrystalpharma.com

Cocrystal Pharma, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that is in Phase 2a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on whatsapp
WhatsApp

AIM All Share Index